Aptargroup Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
7.5%projected annual EPS growth
Analyst Coverage
7analysts covering
FY Revenue (est.)
$4Bnext fiscal year
FY EPS (est.)
$5.52next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 28 Oct 2026 |
| Q3 2026 Earnings Presentation | 30 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Reported Sales Growth Quarterly1,100.0%Target: Flat core sales growth
Adjusted EBITDA Margin Quarterly1,920.0%Target: 20.7% in the prior year
Free Cash Flow Quarterly53MTarget: More than double year-over-year
Watch Items
- Emergency Medicine Destocking Impact
- Beauty and Closures Segment Margin CompressionTrigger: Beauty margin at 11.1% (down 100 bps) and Closures margin at 13.1% (down 270 bps)
- CEO Leadership TransitionTrigger: Effective September 1, 2026Action: Oversee transition from Stephan B. Tanda to Gael Touya, ensuring seamless strategic continuity.
Research as of 19 Jun 2026